文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

新型快速PCR检测结核分枝杆菌rpoB Ile491Phe利福平耐药突变

Novel rapid PCR for the detection of Ile491Phe rpoB mutation of Mycobacterium tuberculosis, a rifampicin-resistance-conferring mutation undetected by commercial assays.
PubMed 文献 · Clin Microbiol Infect · 2016-12-18

本研究设计了一种实时多重等位特异性PCR方法,用于检测商业试剂盒漏检的rpoB Ile491Phe突变。在78株斯威士兰菌株中,该方法与rpoB测序结果100%一致。作者建议在常规诊断中将该突变检测作为商业方法的补充,尤其在该突变高频国家。

要点

  • 商业分子检测及MGIT液体培养可漏检斯威士兰高达30%的利福平耐药结核菌株。
  • 新设计实时多重等位特异性PCR可检出rpoB Ile491Phe突变。
  • 该方法与rpoB测序在78株斯威士兰菌株中结果100%一致。

核心结论

  • 检测rpoB Ile491Phe突变应补充商业方法用于利福平耐药结核诊断,尤其在该突变高频国家。

研究设计与样本

  • 设计实时多重等位特异性PCR方法,以78株斯威士兰菌株与rpoB测序比较。

主要发现

  • 新PCR方法与rpoB测序在78株斯威士兰菌株中显示100%一致性。

关键数值与推荐

  • 斯威士兰高达30%的利福平耐药结核菌株因rpoB Ile491Phe突变被MGIT、Xpert MTB/RIF和MTBDRplus V2.0漏检。

临床怎么用

  • 在常规条件下,将rpoB Ile491Phe突变检测作为商业试剂盒的补充,尤其用于该突变高频国家。
  • 该方法适用于大多数参考实验室。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Neither the liquid medium-based Bactec MGIT, nor commercial molecular assays such as the Xpert MTB/RIF and the MTBDRplus V2.0 assays are capable of detecting up to 30% of rifampicin-resistant Mycobacterium tuberculosis strains in Swaziland because of the large proportion of the rpoB Ile491Phe mutations. In other countries, the frequency of this mutation is thought to be low. METHODS: We designed a real-time multiplex allele-specific PCR assay to identify the rpoB Ile491Phe mutation responsible for these undetected resistant M. tuberculosis strains. RESULTS: The technique showed 100% similarity with rpoB sequencing on a panel of 78 strains from Swaziland. CONCLUSIONS: We propose that the detection of the rpoB Ile491Phe rpoB mutation should complement commercial assays for the diagnosis of rifampicin-resistant M. tuberculosis in routine conditions, particularly in countries where this specific mutation is frequent. The technique proposed in this paper is adapted for most reference laboratories.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. André E, Goeminne L, Colmant A, et al. Novel rapid PCR for the detection of Ile491Phe rpoB mutation of Mycobacterium tuberculosis, a rifampicin-resistance-conferring mutation undetected by commercial assays. Clin Microbiol Infect. 2016. PMID: 27998822. doi:10.1016/j.cmi.2016.12.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。